InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,479.33
(
-0.14%
)
US TECH 100
19,245.18
(
-0.84%
)
Dow Jones
39,141.54
(
0.79%
)
Brent Oil
85.11
(
0.48%
)
Bitcoin
64,979.88
(
0.02%
)
Post# of 4856
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

08190819

Send PM Follow Ignore
Followers 1
Posts 40
Boards Moderated 0
Alias Born 07/02/2013

08190819

Re: 08190819 post# 4382

Wednesday, 01/11/2017 9:15:55 PM

Wednesday, January 11, 2017 9:15:55 PM

Post# of 4856
NEURALSTEM’s patent-protected technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The Company expects that its first Investigational New Drug application will be for the treatment of Ischemic Paraplegia, a form of paraplegia that sometimes results from the surgery to repair aortic aneurysms and for which there is no effective treatment.

https://newburghpress.com/2017/01/11/neuralstem-inc-nasdaqcur-hit-its-52-week-high-of-6-07-on-jan-10-2017/
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up